| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8738569 | International Journal of Antimicrobial Agents | 2018 | 42 Pages |
Abstract
Overall, low-quality data suggest that IVCC did not lower mortality in patients with MDR Gram-negative infections. However, there is some evidence for a benefit observed with high intravenous doses of colistin.
Related Topics
Life Sciences
Immunology and Microbiology
Applied Microbiology and Biotechnology
Authors
Konstantinos Z. Vardakas, Andreas D. Mavroudis, Maria Georgiou, Matthew E. Falagas,